Declared bankruptcy in Sep 2023
NMTR - 9 Meters Biopharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Raleigh,
United States
Type: Equity
NMTR price evolution
NMTR
| (in millions $) | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.62 | $29.66 | $39.4 | $29.46 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $9.2 | $33.02 | $18.45 | $31.35 |
| Long term investments | ||||
| Property, plant & equipment | $0.11 | $0.12 | $0.14 | $0.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.12 | $0.13 | $23.68 | $0.16 |
| Total investments | ||||
| Total assets | $9.31 | $33.15 | $42.14 | $31.51 |
| Current liabilities | ||||
| Accounts payable | $4.23 | $5.05 | $1.44 | $2.33 |
| Deferred revenue | ||||
| Short long term debt | $5.07 | $19.62 | $2.65 | |
| Total current liabilities | $15.58 | $30.7 | $12.86 | $9.34 |
| Long term debt | $0.03 | $0.05 | $15.81 | $0.08 |
| Total noncurrent liabilities | $0.03 | $0.05 | $15.81 | $0.08 |
| Total debt | $5.11 | $19.67 | $18.46 | $0.08 |
| Total liabilities | $15.61 | $30.75 | $28.67 | $9.42 |
| Shareholders' equity | ||||
| Retained earnings | -$226.48 | -$212.61 | -$200.68 | -$191.32 |
| Other shareholder equity | ||||
| Total shareholder equity | -$6.3 | $2.4 | $13.46 | $22.09 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $29.66 | $46.99 | $37.85 | $4.59 |
| Short term investments | $0.07 | $0.07 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $33.02 | $49.99 | $38.93 | $5.22 |
| Long term investments | ||||
| Property, plant & equipment | $0.12 | $0.18 | $0.23 | $0.07 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.13 | $0.19 | $0.23 | $0.07 |
| Total investments | $0.07 | $0.07 | ||
| Total assets | $33.15 | $50.17 | $39.16 | $5.3 |
| Current liabilities | ||||
| Accounts payable | $5.05 | $2.43 | $1.49 | $3.89 |
| Deferred revenue | ||||
| Short long term debt | $19.62 | $0.01 | $3.18 | |
| Total current liabilities | $30.7 | $8.46 | $6.85 | $14.91 |
| Long term debt | $0.05 | $0.11 | $0.17 | |
| Total noncurrent liabilities | $0.05 | $0.11 | $0.17 | |
| Total debt | $19.67 | $0.11 | $0.18 | $3.18 |
| Total liabilities | $30.75 | $8.57 | $7.02 | $14.91 |
| Shareholders' equity | ||||
| Retained earnings | -$212.61 | -$168.84 | -$132.06 | -$70.56 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | $2.4 | $41.6 | $32.14 | -$9.61 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $9.8 | $8.79 | $6.3 | $7.55 |
| Selling, general & administrative | $2.99 | $1.95 | $2.42 | $3.65 |
| Total operating expenses | $12.79 | $10.74 | $8.72 | $11.2 |
| Operating income | -$12.79 | -$10.74 | -$8.72 | -$11.2 |
| Income from continuing operations | ||||
| EBIT | -$13.12 | -$10.11 | -$8.51 | -$11.13 |
| Income tax expense | ||||
| Interest expense | $0.75 | $1.82 | $0.85 | |
| Net income | ||||
| Net income | -$13.87 | -$11.93 | -$9.35 | -$11.13 |
| Income (for common shares) | -$13.87 | -$11.93 | -$9.35 | -$11.13 |
| (in millions $) | 31 Dec 2022 | 30 Jan 2022 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $31.01 | $10.93 | $13.72 | |
| Selling, general & administrative | $11.01 | $10.52 | $10.57 | |
| Total operating expenses | $42.02 | $53.72 | $24.28 | |
| Operating income | -$42.02 | -$53.72 | -$24.28 | |
| Income from continuing operations | ||||
| EBIT | -$41.1 | -$57.45 | -$25.22 | |
| Income tax expense | ||||
| Interest expense | $2.67 | $4.05 | $1.83 | |
| Net income | ||||
| Net income | -$43.77 | -$61.5 | -$27.05 | |
| Income (for common shares) | -$43.77 | -$61.5 | -$27.05 | |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$13.87 | -$11.93 | -$9.35 | -$11.13 |
| Operating activities | ||||
| Depreciation | $0 | $0 | $0 | $0 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.74 | $0.74 | $0.73 | $1.77 |
| Total cash flows from operations | -$9.75 | -$9.74 | -$9.97 | -$7.79 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5 | |||
| Net borrowings | -$16.75 | $19.91 | ||
| Total cash flows from financing | -$12.29 | $19.91 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.04 | -$9.74 | $9.94 | -$7.79 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$43.77 | -$36.78 | -$61.5 | -$27.05 |
| Operating activities | ||||
| Depreciation | $0.01 | $0.01 | $0.02 | $0.02 |
| Business acquisitions & disposals | -$2.49 | -$3.18 | ||
| Stock-based compensation | $3.94 | $2.41 | $4.72 | $2.87 |
| Total cash flows from operations | -$37.24 | -$29.48 | -$19.41 | -$17.97 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.01 | -$0 | -$0.01 |
| Investments | $0.07 | |||
| Total cash flows from investing | -$0 | -$2.43 | -$3.19 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $44.01 | $39.68 | $20.74 | |
| Net borrowings | $19.91 | -$0.06 | $0.02 | -$2.85 |
| Total cash flows from financing | $19.91 | $41.05 | $55.86 | $16.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$17.33 | $9.14 | $33.26 | -$1.14 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 14.34M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$42.86M |
| EBIT | -$42.86M |
| Net Income | -$46.28M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -0.44 |
| Cash/Share | 0.53 |
| EPS | -$3.23 |
|---|---|
| ROA | -159.45% |
| ROE | -584.98% |
| Debt/Equity | 12.81 |
|---|---|
| Net debt/EBITDA | -0.19 |
| Current ratio | 0.59 |
| Quick ratio | 0.59 |